News | August 01, 2025
Bliss GVS Pharma posts Q1 FY26 PAT higher at Rs. 43.03 Cr
Bliss GVS Pharma has reported total income of Rs. 242.92 crores during the period ended June 30, 2025
Bliss GVS Pharma has reported total income of Rs. 242.92 crores during the period ended June 30, 2025
Our specialty chemical businesses have continued to perform strongly, growing double digit YoY
NewCo’s pipeline includes five investigational medicines
Roche also shared the design of its upcoming Phase III TRONTIER 1 and 2 trials investigating trontinemab in people with early symptomatic Alzheimer’s disease
He most recently served as Chief Medical Officer of AstraZeneca and Alexion
Trixeo is the first pMDI medicine in AstraZeneca’s portfolio to use the near-zero GWP propellant
Elevidys is currently the only approved gene therapy that targets the root cause of Duchenne
For patients with resectable early-stage gastric and gastroesophageal junction cancers
The Genexus platform enables Next-Generation Sequencing with significantly faster turnaround times
Novo Nordisk will merge its Research & Early Development and Development functions into a single R&D unit
Subscribe To Our Newsletter & Stay Updated
